Resistant hypertension remains a major challenge for patients with chronic kidney disease, contributing to elevated cardiovascular and kidney failure risk. This session will provide an update on renal denervation, an innovative treatment for resistant hypertension. Faculty will discuss renal denervation technology, data, physiological effects, recent FDA approvals, and potential clinical applications.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Specialties served/covered
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 1 credit
- MOC · Up to 1 point
- Commercial Support
-
ReleasedJul 27, 2026
-
Last day to claim creditJul 29, 2027 10 months left
